P 021
Alternative Names: P-021; PB-021Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Phanes Biotech
- Class Antidementias; Small molecules
- Mechanism of Action Brain derived neurotrophic factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 07 Nov 2024 Preclinical trials in Alzheimer's disease in USA (unspecified route) prior to November 2024 (Phanes Biotech Pipeline, November 2024)
- 07 Nov 2024 Pharmacodynamics data from a preclinical study in Alzheimer’s disease released by Phase Biotech prior to November 2024 (Phanes Biotech Pipeline, November 2024)